INTCO Medical, a global disposable-glove manufacturer listed as 300677.SZ, reported revenue of RMB 6.91 billion (about $1.03 billion) for the six months ended June 30, 2026, up 40.61% from a year earlier. Net profit attributable to shareholders rose 17.86% to RMB 837.3 million (about $124.6 million), while adjusted net profit attributable to shareholders, excluding one-off gains and losses, jumped 165.00% to RMB 1.06 billion (about $157.7 million). By the end of the reporting period, annual production capacity had reached 107 billion disposable gloves, comprising 74 billion nitrile gloves and 33 billion vinyl gloves. INTCO Medical said the scale reinforced its position as the world’s largest disposable-glove producer. Its integrated value chain covers nitrile latex, research and development and manufacturing of core production equipment, glove production and global sales. Stakes in nitrile-latex manufacturers help secure raw-material supplies, reduce the effect of international crude-oil price fluctuations on key material costs, and improve supply stability and cost efficiency. Coordinated domestic and international capacity allows the company to allocate production resources to market demand, respond to customers and support deliveries worldwide. Research and development spending rose 20.62% to RMB 245.9 million (about $36.6 million). During the period, the company continued developing products including Syntex™ Synthetic Latex Gloves, an internally developed glove without natural latex proteins that offers high elasticity and puncture resistance, and Synmax Pro Exam Gloves, an upgraded vinyl glove for hospitality and industrial uses. It also introduced household gloves, safety gloves and other products for different applications. INTCO Medical’s latest nitrile-glove production line extends more than 1.6 kilometers and has about 500 control points. Its distributed precision-control system automatically manages temperature and liquid levels according to production conditions, reducing labor and energy consumption while supporting stable output. Product yield remained above 99% during the reporting period. INTCO Medical said it will continue optimizing global capacity and advancing protective-product innovation to support growth.